section name header

Pronunciation

ba-LOX-A-veer

Classifications

Therapeutic Classification: antivirals

Pharmacologic Classification: endonuclease inhibitors

Indications

REMS


Action

  • Inhibits the endonuclease activity of the polymerase acidic protein in the viral RNA polymerase complex that is required for viral gene transcription, thereby resulting in inhibition of influenza virus replication.
Therapeutic effects:
  • Reduced duration of flu-related symptoms.

Pharmacokinetics

Absorption: Administered as a prodrug (baloxavir marboxil), which is rapidly absorbed from the GI tract and converted by the liver to the active form, baloxavir.

Distribution: Extensively distributed to tissues.

Protein Binding: 93–94%.

Metabolism/Excretion: Rapidly metabolized by the liver by UGT1A3 to baloxavir, the active metabolite. Primarily excreted in feces (80%); 15% excreted in urine (3% as active metabolite).

Half-Life: 79 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown4 hrunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Xofluza